

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Megna Michael R</u>			2. Issuer Name and Ticker or Trading Symbol <u>Kiniksa Pharmaceuticals, Ltd. [KNSA]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) CHIEF ACCOUNTING OFFICER		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>02/28/2024</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O KINKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET			4. If Amendment, Date of Original Filed (Month/Day/Year)			Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		
(Street)								
HAMILTON	DO	HM 11						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Common Share	01/15/2024		A ⁽¹⁾		583	A	\$12.35	17,588	D	
Class A Common Share	02/28/2024		M ⁽²⁾		5,126	A	\$8.83	22,714	D	
Class A Common Share	02/28/2024		S ⁽²⁾		5,126	D	\$21.79 ⁽³⁾	17,588	D	
Class A Common Share	03/01/2024		M ⁽²⁾		5,645	A	\$8.83	23,233	D	
Class A Common Share	03/01/2024		M ⁽²⁾		4,014	A	\$13.88	27,247	D	
Class A Common Share	03/01/2024		S ⁽²⁾		9,659	D	\$21.45 ⁽⁴⁾	17,588	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Amount or Number of Shares
Share Option	\$8.83	02/28/2024		M ⁽²⁾			5,126	(5)	09/16/2029	Class A Common Share	5,126	\$0	5,874	D	
Share Option	\$8.83	03/01/2024		M ⁽²⁾			5,645	(5)	09/16/2029	Class A Common Share	5,645	\$0	229	D	
Share Option	\$13.88	03/01/2024		M ⁽²⁾			4,014	(5)	08/05/2028	Class A Common Share	4,014	\$0	0	D	

Explanation of Responses:

- The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2023 to January 15, 2024. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
- This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$21.56 to \$21.90. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$21.45 to \$21.49. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This option is fully vested and exercisable.

/s/ Madelyn Zeylikman,
Attorney-in-Fact

03/01/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.